OXiGENE regains compliance for continued listing on NASDAQ Global Market

NewsGuard 100/100 Score
Apr 7 2010

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2) requiring the Company to have at least three independent directors on its audit committee for continued listing on the NASDAQ Global Market, and this matter is now closed.

Source:

 OXiGENE

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

Study links air pollution to increased colorectal cancer risk through DNA changes
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer
Liver cells effectively serve as immune checkpoint regulating anti-cancer immunity
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer
Breast cancer survivors at higher risk of developing second cancers
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Researchers aim to use AI for early screening and prognosis of Dry Eye Disease

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New technique allows scientists to study the fatty contents of cancer cells